Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sirnaomics Ltd. ( (HK:2257) ) has provided an update.
Sirnaomics Ltd., a Hong Kong-listed biopharmaceutical company specializing in RNAi-based therapeutics, reported a change in its ownership structure following a share purchase by its chairman. The group continues to position itself as an innovator in RNA-targeted drug development for oncology and other serious conditions, addressing both domestic and international markets.
Chairman and executive director Dr. Poon Hung Fai acquired 38,000 Sirnaomics shares on the open market at an average price of about HK$5.93 per share, increasing his interest to 17,665,696 shares, or 16.10% of the company’s issued share capital. The purchase, funded personally, signals Dr. Poon’s confidence in the group’s development prospects and potential growth, while the company cautioned shareholders and potential investors to exercise care when trading its securities.
The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.
More about Sirnaomics Ltd.
Sirnaomics Ltd. is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange under stock code 2257. The group operates in the biopharmaceutical sector, focusing on the development of RNAi-based therapeutics and related drug platforms, primarily targeting global markets for innovative treatments in oncology and other serious diseases.
Average Trading Volume: 290,508
Technical Sentiment Signal: Sell
Current Market Cap: HK$650.6M
Learn more about 2257 stock on TipRanks’ Stock Analysis page.